Reports Q4 revenue $942.00M, consensus $ $922.92M."2022 marked another impressive year for Horizon (HZNP), with double-digit net sales growth across our commercial portfolio and significant progress executing on our strategy to maximize the value of our growth medicines, expand our global presence and advance our pipeline, including generating positive topline results from our Phase 2 trial in Sjogren’s syndrome across both patient populations," said Tim Walbert, chairman, president and chief executive officer, Horizon. "I am extremely proud of what we have accomplished – not only in the last year, but over the last decade. We have built a leading, innovation-driven, profitable biotechnology company that is well-positioned going forward as we prepare to become part of Amgen (AMGN)."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HZNP:
- Horizon updates Uplizna data from analyses of the N-MOmentum trial for NMOSD
- George Soros Makes Major Changes to His Stock Positions
- Horizon Pharma put volume heavy and directionally bearish
- Horizon Pharma call volume above normal and directionally bullish
- Amgen price target lowered to $275 from $285 at Wells Fargo
